Suggested Reading
Ajani JA, Walsh G, Komaki R, et al: Preoperative induction of CPT-111 and cisplatin(Drug information on cisplatin) chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100:2347–2354, 2004.
Bedenne L, Michel P, Bouche O, et al: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160–1168, 2007.
Conroy T, Yataghène Y, Etienne PL, et al: Phase II randomised trial of chemotherapy with FOLFOX4 or cisplatin plus fluorouracil(Drug information on fluorouracil) in oesophageal cancer. Br J Cancer 103:1349–1355, 2010.
Cunningham D, Starling N, Rao S, et al: Capecitabine(Drug information on capecitabine) and oxaliplatin(Drug information on oxaliplatin) for advanced esophagogastric cancer. N Engl J Med 358:36–46, 2008.
De Vita F, Orditura M, Innocente R, et al: Induction primary CT with Folfox-4 and cetuximab(Drug information on cetuximab) followed by RT and cetuximab in locally advanced esophageal cancer (LAEC): Analysis of preliminary data from B152 Trial. J Clin Oncol 26(suppl):abstract 15524, 2008.
El-Rayes BF, Shields A, Zalupski M, et al: A phase II study of carboplatin(Drug information on carboplatin) and paclitaxel(Drug information on paclitaxel) in esophageal cancer. Ann Oncol 15:960–965, 2004.
Enzinger PC, Burtness B, Hollis D, et al: CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 28(15s):abstract 4006, 2010.
Ferry DR, Anderson M, Beddard K, et al: A phase II study of gefitinib(Drug information on gefitinib) monotherapy in advanced esophageal adenocarcinoma: Evidence of gene expression, cellular, and clinical response. Clin Cancer Res 13:5869–5875, 2007.
Igaki H, Kato H, Ando N, et al: A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). J Clin Oncol 26:abstract 4510, 2008.
Ilson DH, Kelsen D, Shah M, et al: A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 117:1409–1404, 2011.
Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al: Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 24:1612–1619, 2006.
Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277–300, 2010.
Kachnic LA, Winter K, Wasserman T, et al: Logitudinal quality-of-life analysis of RTOG 94-05 (Int 0123): A phase III trial of definitive chemoradiotherapy for esophageal cancer. Gastrointest Cancer Res 4:45–52, 2011.
Kim JY, Do YR, Park KU, et al: A multi-center phase II study of docetaxel(Drug information on docetaxel) plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol 66:31–36, 2010.
Lee DH, Kim HT, Han JY, et al: A phase II trial of modified weekly irinotecan(Drug information on irinotecan) and cisplatin for chemotherapy-naive patients with metastatic or recurrent squamous cell carcinoma of the esophagus. Cancer Chemother Pharmacol 61:83–88, 2008.
Li G, Hu W, Wang J, et al: Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys 78:1407–1412, 2010.
Lin SH, Komaki R, Liao Z, et al: Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 83:e345–e351, 2012.
Lordick F, von Schilling C, Bernhard H, et al: Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 89:630–633, 2003.
Lorenzen S, Duyster J, Lersch C, et al: Capecitabine plus docetaxel every 3 weeks in first- and second-line metastastic oesophageal cancer: Final results of a phase II trial. Br J Cancer 92:2129–2133, 2005.
Lorenzen S, Schuster T, Porschen R, et al: Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 20:1667–1673, 2009.
Mauer AM, Kraut EH, Krauss SA, et al: Phase II trial of oxaliplatin, leucovorin, and fluorouracil in patients with advanced carcincoma of the esophagus. Ann Oncol 16:1320–1325, 2005.
Nallapareddy S, Wilding GE, Yang G, et al: Chemoradiation is a tolerable therapy for older adults with esophageal cancer. Anticancer Res 25:3055–3060, 2005.
Polee MB, Sparreboom A, Eskens FA, et al: A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. Clin Cancer Res 10:1928–1934, 2004.
Radovich D, Kelsen D, Shah M, et al: OSI-774 in advanced esophageal cancer: A phase II study. J Clin Oncol 22(14s):abstract 4077, 2004.
Rice DC, Correa AM, Vaporciyan AA, et al: Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg 79:391–397, 2005.
Ruhstaller T, Pless M, Dietrich D, et al: Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol 29:626–631, 2011.
Santharalingam M, Moughan J, Coia LR, et al: Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J Clin Oncol 23:2325–2331, 2005.
Shah MA, Jhawer M, Ilson DH, et al: Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab(Drug information on bevacizumab) in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 29:868–874, 2011.
Shim HJ, Cho SH, Hwang JE, et al: Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. Am J Clin Oncol 33:624–628, 2010.
Stahl M, Stuschke M, Lehmann N, et al: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310–2317, 2005.
Stahl M, Walz MK, Stuschke M, et al: Phase III comparison of preoperative chemotherapy compared With chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851–856, 2009.
Tebbutt NC, Cummins MM, Sourjina T, et al: Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 102:475–481, 2010.
Urba SG, Chansky K, vanVeldhuizen PJ, et al: Gemcitabine(Drug information on gemcitabine) and cisplatin for patients with metastatic or recurrent esophageal carcinoma: A Southwest Oncology Group Study. Invest New Drugs 22:91–97, 2004.
Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24:4991–4997, 2006.
van der Gaast A, van Hagen P, Hulshof M, et al: Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. J Clin Oncol 28(15s):abstract 4004, 2010.
van Hagen P, Hulshof MC, van Lanschot JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084, 2012.
van Meerten E, Eskens FA, van Gameren EC, et al: First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: A phase II study. Br J Cancer 96:1348–1352, 2007.
